Nvidia’s next quarter looms large as investors look for a fresh catalyst
After shares surged to an all-time high in mid-May, the question for Nvidia’s fiscal Q2 report is whether new guidance and demand outlines can restart momentum.
Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
After shares surged to an all-time high in mid-May, the question for Nvidia’s fiscal Q2 report is whether new guidance and demand outlines can restart momentum.
THE APEX TIMES
Revere Asset Management’s Don Vandenbord says AI-focused capital that starts in software and platforms could broaden into biotech, with Moderna’s stock becoming one of the familiar places to watch.
A new report says Walmart is preparing to start accepting Apple Pay and Google Pay, a change that matters for shoppers who increasingly expect tap-to-pay from major wallet platforms.
A broad market upswing in the latest weekly review came with a split-screen outcome: Moderna jumped on a cancer vaccine development, while gold and bitcoin climbed, but Walmart’s shares fell over the week.
A Yahoo Finance screen using the average brokerage recommendation suggests Amazon shares should be added, but the report also highlights how uniformly positive views can obscure what investors still do not know.
A Bank of America analyst framed a comparison between Apple’s incoming leadership and Tim Cook’s legacy using a single metric: $32 million in market-cap growth every hour during Cook’s tenure.
IREN surged on Monday after Microsoft accepted a Texas data center tied to the Horizon 1 milestone, a development that analysts say can weaken the company’s bear-case. The gain, however, largely evaporated within the first hour of trading.
BJ’s Wholesale Club reported fiscal second-quarter results that came in ahead of Wall Street expectations and said it now expects higher full-year earnings than it previously projected, according to a report published by Yahoo Finance.
Moderna shares jumped and BioNTech rose as traders revisited the same clinical catalyst across multiple sessions, with options activity suggesting the volatility may not be finished.